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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.006Matrix metalloproteinase-3 (MMP-3) plays an important role in intervertebral disc degeneration, a
ubiquitous condition closely linked to low back pain and disability. Elevated expression of syndecan 4, a
cell surface heparan sulfate proteoglycan, actively controls disc matrix catabolism. However, the rela-
tionship between MMP-3 expression and syndecan 4 in the context of inﬂammatory disc disease has not
been clearly deﬁned. We investigated the mechanisms by which cytokines control MMP-3 expression in rat
and human nucleus pulposus cells. Cytokine treatment increased MMP-3 expression and promoter activity.
Stable silencing of syndecan 4 blocked cytokine-mediated MMP-3 expression; more important, syndecan 4
did not mediate its effects through NF-kB or mitogen-activated protein kinase (MAPK) pathways.
However, treatment with MAPK and NF-kB inhibitors resulted in partial blocking of the inductive effect of
cytokines on MMP-3 expression. Loss-of-function studies conﬁrmed that NF-kB, p38a/b2/g/d, and
extracellular signaleregulated kinase (ERK) 2, but not ERK1, contributed to cytokine-dependent in-
duction ofMMP3 promoter activity. Similarly, inhibitor treatments, lentiviral short hairpin-p65, and short
hairpin-IkB kinase b signiﬁcantly decreased cytokine-dependent up-regulation in MMP-3 expression.
Finally, we show that transforming growth factor-b can block the up-regulation of MMP-3 induced by
tumor necrosis factor (TNF)-a by counteracting the NF-kB pathway and syndecan 4 expression. Taken
together, our results suggest that cooperative signaling through syndecan 4 and the TNF receptor 1e
MAPKeNF-kB axis is required for TNF-aedependent expression of MMP-3 in nucleus pulposus cells.
Controlling these pathways may slow the progression of intervertebral disc degeneration and matrix
catabolism. (Am J Pathol 2014, 184: 2560e2572; http://dx.doi.org/10.1016/j.ajpath.2014.06.006)Supported by NIH grants AR050087, AR055655, and AR064733.
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Disclosures: None declared.Low back pain is one of the most prevalent and costly health
problems facing theworld population, with occurrence in 84%of
the population; the total costs exceed $100 billion per year in the
United States alone.1,2 Intervertebral disc degeneration (IVDD) is
one of the major contributors of low back and neck pain and
associated disability.3,4 Nucleus pulposus (NP) cells, which pri-
marily secrete proteoglycan aggrecan and ﬁbrillar collagens tostigative Pathology.
.form the complex extracellular matrix (ECM), are key in main-
taining a healthy disc.5 Loss of NP cells and their dysfunction,
resulting in decreased proteoglycan synthesis, increased expres-
sion of catabolic enzymes, and a shift toward synthesis of ﬁbrotic
SDC4 Regulates MMP-3 Expression in NPmatrix, are hallmarks of disc degeneration. All these pathological
changes diminish the water-binding capacity of the disc, leading
to failure to resist compressive loads in the spine.6
Despite the ubiquitous nature of the spinal pathologies, the
molecular mechanisms of low back paineassociated IVDD
have not been well investigated. Many studies have demon-
strated that there was an increase in expression and activity of
a range of matrix-degrading enzymes in IVDD, including the
matrix metalloproteinase (MMP) and a disintegrin and met-
alloproteinase with thrombospondin motif (ADAMTS) fam-
ilies.7e9 The MMP is a family of metal-dependent proteases
capable of degrading all components of the ECM of con-
nective tissues.10 It was demonstrated by many studies that
elevated MMPs 1, 2, 3, and 13 have been found in degen-
erated IVD.8e11 Active MMP-3 has the ability to degrade
core proteins of disc and cartilage connective matrix com-
ponents, such as proteoglycans, ﬁbronectin, laminin,
elastin,12e14 and collagens II, IX, and X.15 Noteworthy,
MMP-3 can indirectly affect the degradation of cartilagenous
matrix by proteolysis of latent MMPs, including proeMMP-
1, proeMMP-7, and proeMMP-9 into the active forms,16e18
suggesting that MMP-3 may be important in disc pathologies.
Elevated levels of the proinﬂammatory cytokines, including
tumor necrosis factor (TNF)-a and IL-1b, have been reported
in IVDD.19e21 Recent studies have shown that, in disc cells,
MMP-3 expression is induced by these cytokines.22e27 How-
ever, only a handful of these studies have examined the
mechanism of regulation of MMP-3 by cytokines.14,28 Like-
wise, little is known about the intricacies of the signaling
pathways controlling cytokine-mediated MMP-3 expression
during IVDD.29 TNF-aedependent elevated expression of
syndecan 4 (SDC4), a cell surface heparan sulfate proteogly-
can, plays a major role in matrix catabolism through activation
of ADAMTS-5.19,30,31 Although synergistic actions of SDC4
on activity of several chemokines and cytokines have been
demonstrated,32e34 in the context of inﬂammatory disc disease,
it is not yet known if SDC4 contributes to the cellular actions of
TNF-a and if a regulatory relationship exists between MMP-3
expression and SDC4. In the present study, using genetic ap-
proaches, we investigate the mechanisms by which cytokines
TNF-a and IL-1b control expression of MMP-3 in human and
rat NP cells. Our results indicate that, in addition to mitogen-
activated protein kinase (MAPK)eNF-kB axis downstream
of cytokine receptor, cell surface SDC4 is required for TNF-ae
and IL-1bedependent MMP-3 expression in NP cells.
Materials and Methods
Reagents and Plasmids
Plasmids were kindly provided byWen-Ling Shih (Department
of Life Science, Tzu Chi University, Hualien City, Taiwan)
(MMP3-LUC, 2.3-kb human MMP3 promoter in pGL3),35
Jiahui Han (Scripps Institute, La Jolla, CA) (p38aAF,
p38bAF, p38dAF, and p38gAF), Melanie Cobb (University of
Texas SouthwesternMedical Center, Dallas, TX) (ERK-1K71RThe American Journal of Pathology - ajp.amjpathol.organd ERK-2K52R), and Dr. Silvio Gutkind (NIH, Bethesda,
MD) [activator protein (AP)-1 reporter]. Plasmids for short
hairpin (sh)-p65 and sh-IkB kinase (IKK) b in lentiviral FSVsi
vector that co-expresses yellow ﬂuorescent protein (YFP)
were gifts from Dr. Andree Yeremian (University of Lleida,
Lleida, Spain). Lentiviral shRNA plasmids targeting rat Sdc4
were purchased from Genecoepia. Plasmids psPAX2 (number
12260) and pMD2.G (number 12259), developed by Dr. Didier
Trono (École Polytechnique Fédérale de Lausanne, Lausanne,
Switzerland), and 3 nuclear factor for activated T cell
(NFAT)eLuc (number 17870), developed by Dr. Gerald
Crabtree (Stanford University, Stanford, CA), were obtained
fromAddgene (Cambridge,MA). pRL-TK (Promega,Madison,
WI) containing the Renilla reniformis luciferase gene was used
as an internal transfection control. IKKb and p65 antibodies
were from Cell Signaling (Danvers, MA), MMP-3 and SDC4
antibodies were from Abcam (Cambridge, MA), and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH)was fromNovus
Biologicals (Littleton, CO). Recombinant human TNF-a and
IL-1b were purchased from PeproTech, Inc. (Rocky Hill, NJ).Isolation of NP Cells and Treatments
Rat (n Z 16 animals) and human (two samples: aged 33
years, female, autopsy, grade 1, and aged 39 years, male,
surgical waste, grade 2) NP cells were isolated using a
method previously described by Risbud et al.36 Collection of
animal and human tissues for cell isolation was performed as
per approved protocols by Thomas Jefferson University’s
(Philadelphia, PA) Institutional Animal Care and Use Com-
mittee and Institutional Review Board, respectively. NP cells
were passaged and maintained in monolayer in Dulbecco’s
modiﬁed Eagle’s medium (DMEM), together with 10% fetal
bovine serum (FBS), supplemented with antibiotics. To
investigate the effect of cytokines, cells in some groups were
treated with 10 ng/mL IL-1b or 25 to 50 ng/mL TNF-a for 24
hours, with or without 10 mmol/L signaling pathway in-
hibitors SM7368, SB203580, PD98059, and SP60025, and
100 nmol/L Go6983 (Calbiochem, Billerica, MA). Cytokine
doses were based on our previous studies.19Real-Time RT-PCR Analysis
Total RNA was extracted from rat or human NP cells cultured
in 6-cm plates (5  105 cells per plate) using RNAeasy mini
columns (Qiagen, Valencia, CA) and treated with RNase-free
DNase I before elution. Puriﬁed RNA (1 to 2 mg) was used to
synthesize cDNA using EcoDry Premix (Clontech, Mountain
View, CA). Reactions were set up in triplicate in 96-well plates
using 1 mL cDNA together with Fast SYBRGreen PCRMaster
Mix (Applied Biosystems, Foster City, CA) and gene-speciﬁc
primers. Gene expression was quantiﬁed using the StepOne-
Plus real-time PCR system (Applied Biosystems), according to
the manufacturer’s instructions. Hypoxanthine phosphor-
ibosyltransferase 1 was used to normalize the expression of2561
Wang et almRNA.All of the primers were synthesized by Integrated DNA
Technologies, Inc. (Coralville, IA).
Protein Extraction and Western Blot Analysis
After treatment of rat or human NP cells cultured in 10-cm
plates (1  106 cells per plate), conditioned medium was
collected and cells were immediately placed on ice andwashed
with ice-cold Hanks’ balanced salt solution. All of the wash
buffers and the ﬁnal cell lysis/resuspension buffers included
1 protease inhibitor cocktail (Roche Diagnostics, Indian-
apolis, IN), 5 mmol/L NaF, and 200 mmol/L Na3VO4.
Conditioned medium was concentrated using 10-kDa cutoff
protein concentrator columns, following the manufacturer’s
instructions (Millipore, Billerica, MA), and stored at 80C
with protease inhibitors. Total cell or secreted proteins were
resolved by electrophoresis on 8% to 12% SDSepolyacryla-
mide gels and transferred by electroblotting to polyvinylidene
diﬂuoride membranes (Bio-Rad Laboratories, Inc., Berkeley,
CA). The membranes were blocked with 5% nonfat dry milk
in Tris-buffered saline with Tween 20 and incubated overnight
at 4C in 3% nonfat dry milk in Tris-buffered saline with
Tween 20. The antibodies were cross-reactive against both
human and rat MMP-3 (1:1000), SDC4 (1:1000), p65
(1:1000), IKKb (1:1000), or GAPDH (1:3000). Immunolab-
eling was detected using the electrochemiluminescence re-
agent (Amersham Biosciences, Piscataway, NJ).
Transfections and Dual-Luciferase Assay
Cells were seeded to 48-well plates (2  104 cells per well) 1
day before transfection. To measure the effect of IL-1b and
TNF-a on MMP-3, cells were transfected with 250 ng of
MMP-3eLuc with 250 ng pRL-TK plasmid. To investigate the
effect of NF-kB and MAPK on MMP-3 plasmid activity, cells
were cotransfected with 50 to 200 ng of dominant-negative
(DN)eNF-kB, DN-p38a/b/g/d, or DN-ERK1/ERK2, with or
without appropriate backbone vector, 150 ngMMP-3 reporters,
and 150 ng pRL-TK plasmids. In some experiments, cells were
transfectedwith 250 ng ofMMP3 reporter with 250 ng pRL-TK
and treated with 10 mmol/L inhibitors for NF-kB (SM7368),
p38 (SB203580), ERK (PD98059), or c-Jun N-terminal kinase
(JNK; SP60025) (Calbiochem) in the presence of TNF-a or IL-
1b. Lipofectamine 2000 (Invitrogen, Grand Island, NY) was
used as a transfection reagent. For each transfection, plasmids
were premixed with the transfection reagent, and 24 hours after
the transfection, some NP cells were treated with IL-1b and
TNF-a. Forty-eight hours after the transfection (72 hours when
cotransfected with sh-SDC4), NP cells were harvested, and a
Dual-Luciferase reporter assay system (Promega) was used for
sequential measurements of ﬁreﬂy and Renilla luciferase ac-
tivities. Quantiﬁcation of luciferase activities and calculation of
relative ratios were performed using a luminometer (TD-20/20;
Turner Designs, Sunnyvale, CA). At least three independent
transfections were performed, and all analyses were performed
in triplicate.2562Lentiviral Particle Production and Viral Transduction
Human embryonic kidney (HEK) 293T cells were seeded in
10-cm plates (1.3  106 cells per plate) in DMEM with 10%
heat-inactivated FBS 2 days before transfection. Cells were
transfected with 2.5 mg of sh-control (Ctr), sh-p65, or sh-IKKb
plasmids or sh-SDC4 plasmids along with 1.875 mg psPAX2
and 0.625 mg pMD2.G. After 16 hours, transfection medium
from the HEK 293T cell plates was removed and replaced
with DMEM with 5% heat-inactivated FBS and penicillin-
streptomycin. Medium containing lentiviral particles was
collected from the HEK 293T cell plates at 48 to 60 hours after
transfection. Human or rat NP cells were plated in DMEMwith
5% heat-inactivated FBS 1 day before transduction. NP cells in
10-cm plates were transduced with 5 mL of conditioned me-
dium containing viral particles along with 6 mg/mL polybrene.
Twenty-four hours later, themediumwas removed and replaced
with DMEM with 5% heat-inactivated FBS. Cells were har-
vested for mRNA and protein extraction 6 days after trans-
duction. A transduction efﬁciency of 60% to 80%was achieved
as determined from the number of YFP-positive cells.
Statistical Analysis
All experiments were performed at least three independent
times and contained three replicates. Data are presented as
the means  SEM. Differences between groups were
assessed by Student’s t test and analysis of variance.
P < 0.05 was considered statistically signiﬁcant.
Results
TNF-a and IL-1b Increase Mmp3 Gene Expression and
Levels of Active MMP-3 Protein in NP Cells
To test the premise that TNF-a and IL-1b regulate MMP-3
expression and activity in IVDD context, rat NP cells were
treated with TNF-a and IL-1b, and Mmp3 expression was
analyzed by real-time RT-PCR. Treatment with both TNF-a
and IL-1b resulted in dose-dependent (Figure 1, A and B) and
time-dependent (Figure 1, C and D) increases in Mmp3
mRNA levels. Western blot analysis showed that treatment of
rat NP cells with TNF-a and IL-1b increased levels of a 50-
kDa product that corresponds to active MMP-3 protein in
both the cellular fraction (Figure 1E) and the secreted fraction
from the conditioned medium (Figure 1F). Corresponding
densitometric analysis conﬁrmed that an increase in active
MMP-3 in both cellular (Figure 1G) and secreted (Figure 1H)
fractions was signiﬁcant. To investigate whether the regula-
tion of MMP-3 expression is at the transcriptional level, we
measured the activity of a 2.3-kb MMP3 promoter after
cytokine treatment. This promoter fragment has been shown
to contain several transcription factor binding sites, including
NFAT, AP-1, cAMP response element binding protein,
E26 transformation-speciﬁc, STAT, NF-kB, and speciﬁcity
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Figure 1 AeD: Cytokine-dependent expres-
sion of MMP-3 in rat NP cells. Real-time RT-PCR
analysis shows that TNF-a and IL-1b up-regulate the
expression of MMP-3 in a dose- and time-dependent
manner. For time-dependent studies, 50 ng/mL TNF-
a and 10 ng/mL IL-1b were used. Western blot (E
and F) and corresponding densitometric (G and H)
analyses show that treatment of NP cells with TNF-a
or IL-1b signiﬁcantly increases the level of MMP-3 in
cellular protein (E and G) and secreted protein (F
and H) in condition medium. The activity of MMP3
promoter construct (MMP-3eLUC) is signiﬁcantly
induced after treatment of NP cells with TNF-a (I)
and IL-1b (J) in a dose-dependent manner. Values
shown are means  SEM of three independent ex-
periments. *P < 0.05.
SDC4 Regulates MMP-3 Expression in NPMMP3 promoter activity in a dose-dependent manner
(Figure 1, I and J), although IL-1bedependent modulation of
MMP3 promoter activity is only seen at a concentration of 10
ng/mL. Compared with IL-1b, MMP3 was much more
responsive to TNF-a treatment, and TNF-a was, therefore,
selected as a representative cytokine for further studies.
SDC4 Serves as TNF-a Coreceptor and Is Required for
Cytokine-Dependent Induction of MMP-3
To ascertain if SDC4 is required for cytokine-induced
MMP-3 expression in NP cells, we stably suppressedThe American Journal of Pathology - ajp.amjpathol.orgSDC4 expression in human NP cells by transduction with
lentivirus-expressing SDC4-shRNA. There was a robust
green ﬂuorescent protein (GFP) expression by the virally
transduced cells, indicating high-level transduction efﬁ-
ciency and transgene expression (Figure 2A). As expected,
there was a signiﬁcant decrease in SDC4 mRNA
(Figure 2B) and protein (Figure 2, C and D) expression in
NP cells transduced with SDC4-shRNA. Furthermore, we
observed that SDC4 was required for TNF-aedependent
MMP-3 induction. Suppression of SDC4 signiﬁcantly de-
creases the inductive effect of TNF-a on the expression
level of MMP-3 in cellular (Figure 2, E and G) and secreted2563
Wang et al(Figure 2, F and H) protein fractions, as seen by Western
blot and corresponding densitometric analyses.
SDC4 Regulation of MMP-3 Expression Is Independent
of NF-kB and PKC Signaling
We then determined if SDC4 mediates its effect on MMP-3
expression through NF-kB. For this purpose, we ﬁrst treated
rat NP cells with surfen, a potent heparan sulfate inhibitor,
and in parallel silenced Sdc4 expression by Sdc4-shRNA.
Then, we measured activities of a prototypic NF-kBeres-
ponsive reporter and MMP3 promoter (Figure 3A) in the
presence or absence of TNF-a. Surprisingly, heparan sulfate
inhibition (Figure 3, B and C) or silencing of Sdc4
(Figure 3, D and E) did not affect TNF-aedependent in-
duction in activities of both the prototypic NF-kB and
MMP3 reporter. Likewise, activities of prototypic AP-1 and
NFAT reporters were unaffected by Sdc4 suppression (data
not shown), suggesting lack of their involvement in MMP-32564regulation. To further determine whether protein kinase C
(PKC) was responsible for mediating SDC4 action, we
measured cytokine-dependent Mmp3 expression in the
presence of PKC inhibitor, Go6983. Noteworthy, PKC in-
hibition did not result in signiﬁcant changes in cytokine-
dependent Mmp3 mRNA expression (data not shown).
Cytokines Promote MMP-3 Expression through MAPK
and NF-kB
We next investigated the involvement of MAPK and NF-kB
signaling pathways in TNF-ae and IL-1bemediated in-
duction of MMP-3. For these studies, rat NP cells were
treated with pathway-speciﬁc inhibitors before the exposure
of TNF-a and IL-1b. RT-PCR analysis showed that pre-
treatment with inhibitors results in a signiﬁcant suppression
in cytokine-dependentMmp3mRNA expression (Figure 4, A
and B). Although the p38/JNK/ERK inhibitor partially
counteracted the inductive effects of TNF-a and IL-1b onFigure 2 SDC4 controls the cytokine-mediated
increase in levels of active MMP-3 protein. A:
Immunoﬂuorescence detects GFP in human NP
cells transduced with lentivirus co-expressing GFP
and either Sdc4-shRNA (LV-shSDC4) or Ctr-shRNA
(LV-shC), showing a high transduction efﬁciency.
RT-PCR (B), Western blot (C), and corresponding
densitometric (D) analyses of cells transduced with
LV-shC and LV-shSdc4. Expression of SDC4 is
signiﬁcantly blocked by the Sdc4-shRNA compared
with the control. Western blot (E and F) and
densitometric (G and H) analyses of MMP-3
expression in cells transfected with LV-shC and
LV-shSdc4 after TNF-a treatment. The TNF-ae
dependent induction in MMP-3 cellular protein
(E and G) and secreted protein (F and H) is
signiﬁcantly blocked by suppression of SDC4
levels. Values shown are means  SEM of three
independent experiments. *P < 0.05. Original
magniﬁcation, 20 (A). CM, conditioned medium.
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Figure 3 Cytokine-mediated up-regulation of
MMP-3 by SDC4 is independent of NF-kB activity. A:
Schematic showing the organization and binding
sites for kB and other transcription factors in syn-
thetic prototypic NF-kB (NF-kBeLUC) and MMP3
promoter constructs (MMP-LUC). Treatment of rat NP
cells with heparan sulfate inhibitor surfen (B and C)
or cotransfection with Sdc4-shRNA (D and E) does
not block the inductive effect of TNF-a on activities
of the prototypic NF-kB reporter (NF-kBeLUC) (B
and D) or MMP3 promoter construct (MMP3-LUC) (C
and E). Values shown are means  SEM of three
independent experiments. *P < 0.05.
SDC4 Regulates MMP-3 Expression in NPMmp3 mRNA expression, NF-kB inhibitors blocked Mmp3
mRNA expression almost to the basal level. To ascertain the
mechanism of action, cytokine-dependent MMP3 promoter
activity was measured in the presence of pathway inhibitors.
Results showed a strong suppression of promoter activity by
all of the inhibitors in the presence of TNF-a (Figure 4C) and
IL-1b (Figure 4D), indicating that the regulation of MMP-3
expression by MAPK and NF-kB pathways is at the tran-
scriptional level.
Isoform Speciﬁcity of MAPK and Contribution of NF-kB
Pathway in Regulation of MMP3 Promoter Activity
We next used a genetic approach to conﬁrm these ﬁndings and
determined if MAPK regulates MMP-3 expression in an
isoform-speciﬁc manner. Rat NP cells were transfected with
DN-ERK1 or DN-ERK2, or DN-p38a/b2/g/d expression
plasmids and MMP3 promoter activity was measured in
the presence of TNF-a or IL-1b. Although DN-ERK1
(Figure 5A) had little or no effect on the induction of pro-
moter activity by TNF-a and IL-1b, cotransfection with DN-
ERK2 (Figure 5B) inhibited cytokine-dependent induction of
MMP3 promoter. In contrast to isoform-speciﬁc differences ofThe American Journal of Pathology - ajp.amjpathol.orgERK, cotransfection with DN-P38a (Figure 5C), DN-p38b2
(Figure 5D), DN-p38d (Figure 5E), or DN-p38g (Figure 5F)
signiﬁcantly inhibited the cytokine-dependent induction of
MMP3 promoter. Because NF-kB pathway inhibitor robustly
inhibits the cytokine-dependent induction of MMP3 expres-
sion, we ﬁrst evaluated responsiveness of MMP3-Luc to
increasing doses of NF-kB inhibitor. Results showed that
MMP3 promoter activity, induced by TNF-a, is completely
blocked by NF-kB pathway inhibitors, even at the concentra-
tion of 10 mmol/L (Figure 5G). Moreover, when rat NP cells
were cotransfected with IkBaM/(DN)eNF-kB, TNF-
aemediated induction in MMP3 promoter activity was
repressed to the basal level (Figure 5H). Both these experiments
suggested a role of canonicalNF-kB pathway in this regulation.
MAPK and NF-kB Pathway Inhibitors Suppress
Cytokine-Dependent Induction of MMP-3 Protein
Levels
We determined if treatment with MAPK and NF-kB
pathway-speciﬁc inhibitors results in suppression in levels
of active MMP-3 protein. Western blot analysis of cellular
(Figure 6A) and conditioned (Figure 6C) media and2565
Figure 4 MAPK and NF-kB regulation of MMP-
3 expression in rat NP cells. Real-time RT-PCR
analysis of Mmp3 expression in NP cells after
TNF-a (A) and IL-1b (B) treatment for 24 hours,
with or without 10 mmol/L of SB203580, PD98059,
SP60025, or SM7368 (p38, ERK, JNK, and NF-kB
inhibitors, respectively). A signiﬁcant blocking of
cytokine-dependent induction in Mmp3 mRNA
expression is seen by all inhibitors. Increased
activation of MMP3 reporter by TNF-a (C) or IL-1b
(D) is suppressed by both MAPK and NF-kB in-
hibitors. Values shown are means  SEM of three
independent experiments. *P < 0.05.
Wang et alcorresponding densitometric analysis (Figure 6, B and D),
respectively, showed that TNF-aedependent induction in
both cellular and secreted MMP-3 protein levels in rat NP
cells was suppressed by MAPK and NF-kB pathway in-
hibitors. Similarly, a pronounced decrease in the levels of
IL-1bemediated MMP-3 induction in both cellular and
secreted fractions was seen in the presence of MAPK and
NF-kB pathway inhibitors (Figure 6, EeH). Although the
p38/JNK/ERK inhibitor partially counteracted the inductive
effects of cytokine on MMP-3 cell protein expression, NF-
kB inhibitors totally blocked MMP-3 cell protein expres-
sion to the basal level.
Canonical IKKb-p65/RelA Signaling Controls Cytokine-
Mediated MMP-3 Expression in Human NP Cells
To further elucidate if the canonical NF-kB signaling
pathway was involved in regulation of MMP-3 expression,
we silenced expression of p65 and its upstream controller
IKKb. Human NP cells were transduced with lentivirus co-
expressing YFP and IKKb-shRNA, p65-shRNA, or Ctr-
shRNA.MMP-3 expression was then measured after TNF-a
treatment. There was a robust YFP expression in the virally
transduced cells, indicating high-level transduction efﬁ-
ciency and transgene expression (Figure 7A). As expected,
in cells transduced with sh-IKKb and sh-p65, there was a
signiﬁcant decrease in the expression of IKKb and p65
mRNA (Figure 7B) and protein (Figure 7, C and D),
respectively, when compared with cells transduced with
control shRNA. More important, suppression of individual
NF-kB signaling components IKKb and p65 signiﬁcantly
decreased the inductive effect of TNF-a on the expression2566level of MMP-3 cellular (Figure 7, E and G) and secreted
(Figure 7, F and H) protein fractions.
TGF-b Suppresses the Induction of MMP-3 by TNF-a in
NP Cells by Counteracting NF-kB Signaling
Next, we investigated whether the induction of MMP-3 by
TNF-a can be modulated by transforming growth factor
(TGF)-b. We transfected rat NP cells with MMP3-LUC
(Figure 8A) and prototypic NF-kB (Figure 8B) reporters
and measured their activities after TGF-b and/or TNF-a
treatment. As expected, TNF-a increased the activity of
both reporters. In contrast, TGF-b not only decreased the
basal activities, but also completely blocked the inductive
effect of TNF-a (Figure 8, A and B), suggesting that TGF-b
inhibits NF-kB signaling. In addition to its effect on NF-kB,
TGF-b blocked elevated expression of Sdc4 in NP cells
treated with TNF-a (Figure 8C). More important, mRNA
expression of Mmp3, induced by TNF-a, was blocked by
TGF-b to nearly a basal level (Figure 8C). Likewise, an
increase in levels of active MMP-3 protein by TNF-a in
both the cellular (Figure 8, D and E) and secreted (Figure 8,
F and G) protein fractions was blocked in the presence of
TGF-b.
Discussion
This study clearly showed that the expression of MMP-3, a
key enzyme involved in degradation of many prominent ECM
components of the intervertebral disc,11,29 is regulated by the
inﬂammatory cytokines TNF-a and IL-1b. More important,
our experiments, for the ﬁrst time to our knowledge,ajp.amjpathol.org - The American Journal of Pathology
Figure 5 MAPK and NF-kB regulation of
cytokine-mediated induction of MMP3 promoter
activity in rat NP cells. NP cells were cotransfected
with MMP-3eLUC, along with DN-ERK1 (A), DN-
ERK2 (B), DN-p38a (C), DN-p38b2 (D), DN-p38d
(E), DN-p38g (F), or the empty backbone vector.
Cells were treated with TNF-a or IL-1b, and re-
porter activity was measured 24 hours after the
treatment. Cotransfection of DN-ERK1 does not
block cytokine-mediated induction of the reporter
activity, whereas cotransfection of DN-ERK2, DN-
p38a, DN-p38b2, DN-p38d, and DN-p38g results
in robust suppression of cytokine-dependent in-
duction of the MMP3 promoter activity. G: In-
duction of MMP3 by TNF-a can be blocked
completely by NF-kB inhibitor SM7368, even at a
lower dose. H: Cotransfection of DNeNF-kB
completely blocks TNF-aedependent induction in
MMP3 promoter activity by NP cells. Values shown
are means  SEM of three independent experi-
ments. *P < 0.05.
SDC4 Regulates MMP-3 Expression in NPdemonstrate that, in NP cells, SDC4 is necessary to mediate
cytokine-dependent induction of MMP-3 expression.
Although our results conﬁrm that signaling through MAPK
and NF-kB is necessary, it is evident that a separate signaling
event downstream of SDC4 is also required to mediate
cytokine-dependent MMP-3 expression. Our studies address
the intricacies of the signaling network used by inﬂammatory
cytokines to mediate their catabolic effects on NP cells and
may provide novel targets for therapies to mitigate or delay the
onset of intervertebral disc degeneration.
Because MMP-3 has a diverse substrate speciﬁcity that in-
cludes aggrecan, ﬁbronectin, and various collagens,12e15 and
because it indirectly activates several latentMMPs,16e18 many
authorities consider it as the key catabolic enzyme in pro-
moting matrix degradation during disc degeneration.37,38The American Journal of Pathology - ajp.amjpathol.orgKanemoto et al37 demonstrated that the number of MMP-3e
positive cells was signiﬁcantly correlated with the magnetic
resonance imagingebased grade of disc degeneration, and
that the ratio of MMP-3epositive cells in prolapsed lumbar
IVDs was signiﬁcantly higher than in non-prolapsed discs.
Studies by Takahashi et al38 suggested that the 5A allele of
theMMP3 promoter linked to regulation of gene expression
is a likely risk factor for accelerated degenerative changes in
the lumbar disc of elderly persons, whereas Aulisa et al39
suggest that the 5A/5A promoter genotype is associated
with a higher risk of adolescent idiopathic scoliosis, a
deformative condition affecting the spine. Despite a strong
connection of MMP-3 to these disc pathologies, little is
understood of the complexities of the pathways that control
MMP-3 expression and activity in the NP cells. We and others2567
Figure 6 Cytokines promote MMP-3 expression
through MAPK and NF-kB pathways in rat NP cells.
Western blot (A and C) and corresponding densi-
tometric (B and D, respectively) analyses show
that TNF-aedependent induction of MMP-3 in
cellular (A and B) and secreted (C and D) protein
levels in NP cells is blocked by MAPK and NF-kB
pathway inhibitors. Measurement of MMP-3 levels
on IL-1b treatment in both cellular (E and F) and
secreted (G and H) protein fraction shows that
MAPK and NF-kB pathway inhibitors exert a strong
suppressive effect. Values shown are means  SEM
of three independent experiments. *P < 0.05. CM,
conditioned medium; PD, PD98059 (ERK inhibitor);
SB, SB203580 (p38 inhibitor); SM, SM7368 (NF-kB
inhibitor); SP, SP60025 (JNK inhibitor).
Wang et alhave reported increased expression of both IL-1b and TNF-a
in human degenerate NP.20,21 More important, studies have
shown that both these cytokines promote matrix degradation
through increased production of degradative enzymes,
including MMPs and ADAMTS-4/5.22,24,40,41 We, therefore,
ﬁrst conﬁrmed that MMP-3 expression by healthy NP cells
was modulated under the inﬂammatory conditions. A robust
stimulatory effect of cytokine exposure onMMP-3 expression
suggested that the elevation of MMP-3 during degeneration
might be the result of the NP cell stimulation by these agents.
Results of these studies are in agreement with previous reports
that showed MMP-3 production is increased by IL-1b and
TNF-a in NP cells.22e27More important, our promoter studies
showed that the regulation was at the transcript level.
Our earlier study had hinted that SDC4, a cell surface
heparan sulfate proteoglycan, may be required for cytokine-2568dependent MMP-3 expression and activation.19 More
important, SDC4 expression itself is inﬂuenced by TNF-a
and IL-1b through NF-kB, and it is shown to contribute to
aggrecan catabolism by promoting ADAMTS-5 activa-
tion.19,31 To conﬁrm if a regulatory relationship between
MMP-3 and SDC4 exists and to delineate the mode of this
interaction, lentiviral SDC4-shRNA silencing studies were
performed in NP cells. Suppression of SDC4 completely
blocked the cytokine-dependent induction of the MMP-3
protein level. These results are in agreement with known
function of SDC4 in controlling activities of several growth
factors and chemokines in a heparan sulfateedependent
manner.32e34,42,43 Noteworthy, binding of chemokines,
such as CXCL12 and chemokine ligand 5, to SDC4 is
shown to enhance their interaction with cognate receptors
and formation of heteromeric complexes.33,34ajp.amjpathol.org - The American Journal of Pathology
Figure 7 NF-kB regulation of MMP-3 expres-
sion. A: Immunoﬂuorescence detection of YFP in
human NP cells transduced with lentivirus (LV) co-
expressing YFP and either shp65 or shIkkb shows
high transduction efﬁciency. RT-PCR (B) and
Western blot (C) and corresponding densitometric
(D) analyses of cells transduced with LV-shC, LV-
shp65, and LV-shIkkb. Expression of p65 and Ikkb
is signiﬁcantly blocked by the respective shRNAs
compared with the control. Western blot (E and F)
and densitometric (G and H) analyses of MMP-3
expression in cells transfected with LV-shC, LV-
shp65, or LV-shIkkb after TNF-a treatment. The
TNF-aedependent induction in MMP-3 cellular (E
and G) and secreted (F and H) protein is signiﬁ-
cantly blocked by suppression of components of
the NF-kB pathway. Values shown are
means  SEM of three independent experiments.
*P < 0.05. Original magniﬁcation, 20 (A). CM,
conditioned medium.
SDC4 Regulates MMP-3 Expression in NPWe then tested if cross talk between SDC4 and NF-kB
and MAPK pathways downstream to TNF-a was respon-
sible for its action. Although NF-kB regulation of SDC4
expression has been previously demonstrated,19 to our sur-
prise, when NP cells were transduced by SDC4-shRNA or
treated with surfen, the inductive effect of TNF-a on MMP3
promoter and prototypic NF-kB reporter activity remained
unaltered, indicating that SDC4 did not modulate NF-kB
and MAPK pathways. Similarly, failure of PKC inhibitor
Go6983 to affect TNF-aemediated MMP-3 expression
suggested that PKC was not involved. Likewise, unre-
sponsiveness of AP-1 and NFAT reporters to TNF-a and
SDC4 suppression and presence of known AP-1, NFAT,
cAMP response element binding protein, STAT, and SP1
binding sites within 2.3 kb of MMP3 promoter suggestedThe American Journal of Pathology - ajp.amjpathol.orgthat these transcription factors did not mediate SDC4 action
on MMP-3 expression.35 Taken together, these results
suggest that SDC4 contributes in mediating TNF-a action
on MMP-3 expression and that, in addition to canonical NF-
kB and MAPK, a yet unknown, independent downstream
signaling event to SDC4 is necessary for controlling MMP3
transcription. Future experiments are directed at delineating
complexities of signaling through SDC4 in NP cells and at
delineating the identity and nature of the SDC4 regulatory
motif that may possibly lie outside the 2.3-kb promoter used
in this analysis.
There is some evidence implicating that cytokine-
dependent MMP-3 expression in NP cells may be regu-
lated by MAPK and NF-kB signaling, although the details
of the transduction pathway are not known.14,28,442569
Figure 8 TGF-b suppresses the induction of MMP-3 by TNF-a in rat NP cells by modulation of NF-kB. Transfection shows that TGF-b blocks the inductive
effect of TNF-a on activities of MMP-3eLUC (A) and NF-kBeLUC (B). C: TGF-b blocks cytokine-mediated induction in Sdc4 and Mmp3 expression induced by
TNF-a to a nearly basal level. Western blot analysis shows that an increase in MMP-3 level in cellular (D) and secreted fraction in condition medium (F) by
TNF-a can be inhibited by TGF-b. Densitometric analysis of the experiment described in D and F above shows a signiﬁcant suppression in TNF-aedependent
increase in MMP-3 in cellular (E) and secreted (G) fraction by TGF-b. GAPDH was used as a loading control and to calculate relative expression. Values shown
are means  SEM of three independent experiments. H: A model of TNF-aemediated expression of MMP-3 through SDC4 and MAPK/NF-kB axis in NP cells.
Binding of TNF-a to TNF receptor 1 activates downstream MAPK (p38a/b2/d/g, ERK2, and JNK) and NF-kB signaling pathway, resulting in expression of MMP-3
and SDC4. SDC4 is required for TNF-aemediated induction of MMP3 through both MAPK/NF-kB axis and an independent, yet unknown, signaling event. TGF-b
inhibits NF-kB signaling, thereby suppressing both SDC4 and MMP-3 expression, which ultimately leads to prevention of matrix degradation. *P < 0.05. CM,
conditioned medium.
Wang et alNoteworthy, the activity of the MAPK pathway is respon-
sive to TNF-a and IL-1b in NP cells, and these pathways
have been shown to modulate NF-kB signaling.40,45 We,
therefore, ﬁrst explored the contribution of this pathway to
the MMP-3 regulatory system by using both inhibitor and
genetic loss-of-function experiments. A signiﬁcant sup-
pression of TNF-ae and IL-1bemediated MMP-3 expres-
sion by p38-, JNK-, and ERK-speciﬁc inhibitors suggested
that the regulation ofMMP3 transcription by cytokines is more
complex than what was originally thought. This was further
evident when MMP3 promoter activity showed differential
sensitivity to MAPK isoforms; p38a/b2/d/g and ERK2 posi-
tively controlled cytokine-dependent induction of MMP-3,
whereas ERK1 was not involved in the response. On the
basis of these ﬁndings, it is not unreasonable to assume that, by2570controlling the activity of speciﬁc MAPK isoforms, cytokines
regulate the expression of MMP-3 in NP cells.
Inhibitor studies by Wuertz and colleagues28,44 have
suggested that NF-kB activity may play a role in IL-
1bedependent MMP-3 up-regulation in NP cells. To
delineate if canonical NF-kB signaling through the IKKb-
p56/RelA axis is involved in this regulation, we ﬁrst treated
NP cells with canonical pathway-speciﬁc inhibitor in the
presence of cytokines. Results showed that pretreatment with
NF-kB inhibitor results in a signiﬁcant suppression in MMP-
3 mRNA and protein expression and promoter activity to
almost the basal level. This notion was further supported by
loss-of-function genetic experiments using shRNAs targeting
p65 and IKKb. The observed inhibition of TNF-ae
dependent MMP-3 expression after suppression of p65 andajp.amjpathol.org - The American Journal of Pathology
SDC4 Regulates MMP-3 Expression in NPIKKb signaling highlighted the importance of the canonical
NF-kB pathway in controlling MMP3 gene expression.
In addition to the transcriptional induction of MMP-3 by
TNF-a and IL-1b, its expression has also been shown to
respond to a variety of other stimuli, such as nitric oxide46,47
and TGF-b.48 TGF-b is known to control ECM synthesis and
matrix degradation in NP cells.49 However, the role of TGF-b
in cytokine-dependent MMP-3 expression in NP cells is
unknown. Signiﬁcant suppression of TNF-aemediated in-
duction in MMP-3 expression by TGF-b was likely due to an
inhibitory effect on NF-kB signaling. Likewise, this NF-kB
modulation also explains blocking of cytokine-dependent
induction in SDC4 levels in TGF-betreated cells.19 Both
these results suggest that an increase in TGF-b levels seen
during disc degeneration would be expected to preserve
ECM levels by controlling expression and activity of MMP-
3. Taken together, our results clearly suggest that, in NP cells,
TNF-a and IL-1b promote the expression of MMP-3 through
MAPK and NF-kB pathways. Moreover, cytokine TNF-ae
and IL-1bedependent MMP-3 expression requires SDC4.
Modulation of these signaling pathways using small molec-
ular inhibitors may provide a new approach to treat inter-
vertebral disc degeneration and mitigate the catabolic action
of MMP-3.
Acknowledgments
We thankWen-Ling Shih (Tzu Chi University, Hualien City,
Taiwan) for providing MMP3-LUC; Jiahui Han (Scripps
Institute, La Jolla, CA) for providing p38aAF, p38bAF,
p38dAF, and p38gAF; Melanie Cobb (University of Texas
Southwestern Medical Center, Dallas, TX) for providing
ERK-1K71R and ERK-2K52R; Dr. Silvio Gutkind (NIH,
Bethesda,MD) for providingAP-1; andDr.AndreeYeremian
(University of Lleida, Lleida, Spain) for providing FSVsi
vector.
X.W., H.W., H.Y., and J.L. performed experiments and
analyzed the data. M.V.R., I.M.S., and Q.C. designed ex-
periments and analyzed the data. M.V.R. and I.M.S. secured
the funding. All authors were involved in writing of the
paper and approval of the submitted manuscript.
References
1. Balague F, Mannion AF, Pellise F, Cedraschi C: Non-speciﬁc low
back pain. Lancet 2012, 379:482e491
2. Katz JN: Lumbar disc disorders and low-back pain: socioeconomic
factors and consequences. J Bone Joint Surg Am 2006, 88:21e24
3. Arana E, Marti-Bonmati L, Molla E, Costa S: Upper thoracic-spine
disc degeneration in patients with cervical pain. Skeletal Radiol
2004, 33:29e33
4. Livshits G, Popham M, Malkin I, Sambrook PN, Macgregor AJ,
Spector T, Williams FM: Lumbar disc degeneration and genetic factors
are the main risk factors for low back pain in women: the UK Twin
Spine Study. Ann Rheum Dis 2011, 70:1740e1745
5. Feng H, Danfelter M, Stromqvist B, Heinegard D: Extracellular matrix
in disc degeneration. J Bone Joint Surg Am 2006, 88:25e29The American Journal of Pathology - ajp.amjpathol.org6. Urban JP, Roberts S: Degeneration of the intervertebral disc. Arthritis
Res Ther 2003, 5:120e130
7. Rutges JP, Kummer JA, Oner FC, Verbout AJ, Castelein RJ,
Roestenburg HJ, Dhert WJ, Creemers LB: Increased MMP-2 activity
during intervertebral disc degeneration is correlated to MMP-14 levels.
J Pathol 2008, 214:523e530
8. Roberts S, Caterson B, Menage J, Evans EH, Jaffray DC,
Eisenstein SM: Matrix metalloproteinases and aggrecanase: their role
in disorders of the human intervertebral disc. Spine (Phila Pa 1976)
2000, 25:3005e3013
9. PockertAJ,RichardsonSM,LeMaitreCL,LyonM,Deakin JA,ButtleDJ,
Freemont AJ, Hoyland JA: Modiﬁed expression of the ADAMTS en-
zymes and tissue inhibitor of metalloproteinases 3 during human inter-
vertebral disc degeneration. Arthritis Rheum 2009, 60:482e491
10. Murphy G, Hembry RM, Hughes CE, Fosang AJ, Hardingham TE:
Role and regulation of metalloproteinases in connective tissue turn-
over. Biochem Soc Trans 1990, 18:812e815
11. Liu J, Roughley PJ, Mort JS: Identiﬁcation of human intervertebral
disc stromelysin and its involvement in matrix degradation. J Orthop
Res 1991, 9:568e575
12. Chin JR, Murphy G, Werb Z: Stromelysin, a connective tissue-
degrading metalloendopeptidase secreted by stimulated rabbit syno-
vial ﬁbroblasts in parallel with collagenase: biosynthesis, isolation,
characterization, and substrates. J Biol Chem 1985, 260:12367e12376
13. Durigova M, Nagase H, Mort JS, Roughley PJ: MMPs are less efﬁcient
than ADAMTS5 in cleaving aggrecan core protein. Matrix Biol 2011,
30:145e153
14. Studer RK, Gilbertson LG, Georgescu H, Sowa G, Vo N, Kang JD:
p38 MAPK inhibition modulates rabbit nucleus pulposus cell response
to IL-1. J Orthop Res 2008, 26:991e998
15. Wu JJ, Lark MW, Chun LE, Eyre DR: Sites of stromelysin cleavage in
collagen types II, IX, X, and XI of cartilage. J Biol Chem 1991, 266:
5625e5628
16. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ: Stro-
melysin is an activator of procollagenase: a study with natural and
recombinant enzymes. Biochem J 1987, 248:265e268
17. Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N,
Okada Y: Matrix metalloproteinase 7 (matrilysin) from human rectal
carcinoma cells: activation of the precursor, interaction with other
matrix metalloproteinases and enzymic properties. J Biol Chem 1995,
270:6691e6697
18. Ogata Y, Enghild JJ, Nagase H: Matrix metalloproteinase3 (strome-
lysin) activates the precursor for the human matrix metalloproteinase 9.
J Biol Chem 1992, 267:3581e3584
19. Wang J, Markova D, Anderson DG, Zheng Z, Shapiro IM,
Risbud MV: TNF-alpha and IL-1beta promote a disintegrin-like and
metalloprotease with thrombospondin type I motif-5-mediated aggre-
can degradation through syndecan-4 in intervertebral disc. J Biol Chem
2011, 286:39738e39749
20. Le Maitre CL, Hoyland JA, Freemont AJ: Catabolic cytokine
expression in human IVD degeneration: IL-1b and TNFa expression
proﬁle. Arthritis Res Ther 2007, 9:R77
21. Risbud MV, Shapiro IM: Role of cytokines in intervertebral disc degen-
eration: pain and disc content. Nat Rev Rheumatol 2014, 10:44e56
22. Séguin CA, Pilliar RM, Roughley PJ, Kandel RA: Tumor necrosis
factor-alpha modulates matrix production and catabolism in nucleus
pulposus tissue. Spine (Phila Pa 1976) 2005, 30:1940e1948
23. Kim HJ, Yeom JS, Koh YG, Yeo JE, Kang KT, Kang YM, Chang BS,
Lee CK: Anti-inﬂammatory effect of platelet-rich plasma on nucleus
pulposus cells with response of TNF-a and IL-1. J Orthop Res 2013,
32:551e556
24. Millward-Sadler SJ, Costello PW, Freemont AJ, Hoyland JA: Regu-
lation of catabolic gene expression in normal and degenerate human
intervertebral disc cells: implications for the pathogenesis of interver-
tebral disc degeneration. Arthritis Res Ther 2009, 11:R65
25. Kim JS, Ellman MB, Yan D, An HS, Kc R, Li X, Chen D, Xiao G,
Cs-Szabo G, Hoskin DW, Buechter DD, Van Wijnen AJ, Im HJ:2571
Wang et alLactoferricin mediates anti-inﬂammatory and anti-catabolic effects via
inhibition of IL-1 and LPS activity in the intervertebral disc. J Cell
Physiol 2013, 228:1884e1896
26. Phillips KL, Jordan-Mahy N, Nicklin MJ, Le Maitre CL: Interleukin-1 re-
ceptor antagonist deﬁcientmiceprovide insights intopathogenesis of human
intervertebral disc degeneration. Ann Rheum Dis 2013, 72:1860e1867
27. Fujita K, Ando T, Ohba T, Wako M, Sato N, Nakamura Y, Ohnuma Y,
Hara Y, Kato R, Nakao A, Haro H: Age-related expression of MCP-1
and MMP-3 in mouse intervertebral disc in relation to TWEAK and
TNF-a stimulation. J Orthop Res 2012, 30:599e605
28. Wuertz K, Quero L, Sekiguchi M, Klawitter M, Nerlich A, Konno S,
Kikuchi S, Boos N: The red wine polyphenol resveratrol shows prom-
ising potential for the treatment of nucleus pulposus-mediated pain
in vitro and in vivo. Spine (Phila Pa 1976) 2011, 36:E1373eE1384
29. Canbay S, Turhan N, Bozkurt M, Arda K, Caglar S: Correlation of
matrix metalloproteinase-3 expression with patient age, magnetic
resonance imaging and histopathological grade in lumbar disc degen-
eration. Turk Neurosurg 2013, 23:427e433
30. Bertrand J, Stange R, Hidding H, Echtermeyer F, Nalesso G,
Godmann L, Timmen M, Bruckner P, Dell’Accio F, Raschke MJ,
Pap T, Dreier R: Syndecan 4 supports bone fracture repair, but not fetal
skeletal development, in mice. Arthritis Rheum 2013, 65:743e752
31. Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer K,
Fuerst M, Lee YJ, Song YW, Herzog C, Theilmeier G, Pap T: Syn-
decan-4 regulates ADAMTS-5 activation and cartilage breakdown in
osteoarthritis. Nat Med 2009, 15:1072e1076
32. Jiang D, Liang J, Campanella GS, Guo R, Yu S, Xie T, Liu N, Jung Y,
Homer R, Meltzer EB, Li Y, Tager AM, Goetinck PF, Luster AD,
Noble PW: Inhibition of pulmonary ﬁbrosis in mice by CXCL10 re-
quires glycosaminoglycan binding and syndecan-4. J Clin Invest 2010,
120:2049e2057
33. Charnaux N, Brule S, Hamon M, Chaigneau T, Saffar L, Prost C,
Lievre N, Gattegno L: Syndecan-4 is a signaling molecule for stromal
cell-derived factor-1 (SDF-1)/CXCL12. FEBS J 2005, 272:1937e1951
34. Slimani H, Charnaux N, Mbemba E, Saffar L, Vassy R, Vita C,
Gattegno L: Binding of the CC-chemokine RANTES to syndecan-1
and syndecan-4 expressed on HeLa cells. Glycobiology 2003, 13:
623e634
35. Shih WL, Liao MH, Yu FL, Lin PY, Hsu HY, Chiu SJ: AMF/PGI
transactivates the MMP-3 gene through the activation of Src-RhoA-
phosphatidylinositol 3-kinase signaling to induce hepatoma cell
migration. Cancer Lett 2008, 270:202e217
36. Risbud MV, Guttapalli A, Stokes DG, Hawkins D, Danielson KG,
Schaer TP, Albert TJ, Shapiro IM: Nucleus pulposus cells express
HIF-1 alpha under normoxic culture conditions: a metabolic adaptation
to the intervertebral disc microenvironment. J Cell Biochem 2006, 98:
152e159
37. Kanemoto M, Hukuda S, Komiya Y, Katsuura A, Nishioka J: Immu-
nohistochemical study of matrix metalloproteinase-3 and tissue2572inhibitor of metalloproteinase-1 human intervertebral discs. Spine
(Phila Pa 1976) 1996, 21:1e8
38. Takahashi M, Haro H, Wakabayashi Y, Kawa-uchi T, Komori H,
Shinomiya K: The association of degeneration of the intervertebral disc
with 5a/6a polymorphism in the promoter of the human matrix
metalloproteinase-3 gene. J Bone Joint Surg Br 2001, 83:491e495
39. Aulisa L, Papaleo P, Pola E, Angelini F, Aulisa AG, Tamburrelli FC,
Pola P, Logroscino CA: Association between IL-6 and MMP-3 gene
polymorphisms and adolescent idiopathic scoliosis: a case-control
study. Spine (Phila Pa 1976) 2007, 32:2700e2702
40. Tian Y, Yuan W, Fujita N, Wang J, Wang H, Shapiro IM, Risbud MV:
Inﬂammatory cytokines associated with degenerative disc disease
control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus
cells through MAPK and NF-kappaB. Am J Pathol 2013, 182:
2310e2321
41. Le Maitre CL, Freemont AJ, Hoyland JA: The role of interleukin-1 in
the pathogenesis of human intervertebral disc degeneration. Arthritis
Res Ther 2005:R732eR745
42. Fuerer C, Habib SJ, Nusse R: A study on the interactions between
heparan sulfate proteoglycans and Wnt proteins. Dev Dyn 2010, 239:
184e190
43. Chang SC, Mulloy B, Magee AI, Couchman JR: Two distinct sites in
sonic Hedgehog combine for heparan sulfate interactions and cell
signaling functions. J Biol Chem 2011, 286:44391e44402
44. Klawitter M, Quero L, Klasen J, Liebscher T, Nerlich A, Boos N,
Wuertz K: Triptolide exhibits anti-inﬂammatory, anti-catabolic as well
as anabolic effects and suppresses TLR expression and MAPK activity
in IL-1b treated human intervertebral disc cells. Eur Spine J 2012, 21:
S850eS859
45. Wang J, Tian Y, Phillips KL, Chiverton N, Haddock G, Bunning RA,
Cross AK, Shapiro IM, Le Maitre CL, Risbud MV: Tumor necrosis
factor a- and interleukin-1b-dependent induction of CCL3 expression
by nucleus pulposus cells promotes macrophage migration through
CCR1. Arthritis Rheum 2013, 65:832e842
46. Loffek S, Schilling O, Franzke CW: Series “matrix metalloproteinases
in lung health and disease”: biological role of matrix metal-
loproteinases: a critical balance. Eur Respir J 2011, 38:191e208
47. Akool el-S, Kleinert H, Hamada FM, Abdelwahab MH, Forstermann U,
Pfeilschifter J, Eberhardt W: Nitric oxide increases the decay of matrix
metalloproteinase 9 mRNA by inhibiting the expression of mRNA-
stabilizing factor HuR. Mol Cell Biol 2003, 23:4901e4916
48. Xie J, Wang C, Huang DY, Zhang Y, Xu J, Kolesnikov SS, Sung KL,
Zhao H: TGF-beta1 induces the different expressions of lysyl oxidases
and matrix metalloproteinases in anterior cruciate ligament and medial
collateral ligament ﬁbroblasts after mechanical injury. J Biomech
2013, 46:890e898
49. Lee YJ, Kong MH, Song KY, Lee KH, Heo SH: The relation between
Sox9, TGF-beta1, and proteoglycan in human intervertebral disc cells.
J Korean Neurosurg Soc 2008, 43:149e154ajp.amjpathol.org - The American Journal of Pathology
